Adenosine for vasoreactivity testing in pulmonary hypertension: A head-to-head comparison with inhaled nitric oxide

Respiratory Medicine

Volumn 104, Issue 4, 2010, Pages 606-611

  Oliveira, Edmundo C ^a   Ribeiro, Antonio Luiz P ^a   Amaral, Carlos Faria Santos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adenosine; Diagnosis; Nitric oxide; Pulmonary hypertension

Indexed keywords

ADENOSINE; NITRIC OXIDE; VASODILATOR AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BRADYCARDIA; BRONCHOSPASM; CHILD; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; THORAX PAIN; VASODILATATION; DRUG EFFECTS; DRUG POTENTIATION; HEART OUTPUT; HYPERTENSION, PULMONARY; INHALATIONAL DRUG ADMINISTRATION; LUNG CIRCULATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOPHYSIOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT;

ADENOSINE; ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; CARDIAC OUTPUT; CHILD; CHILD, PRESCHOOL; DRUG SYNERGISM; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NITRIC OXIDE; PULMONARY CIRCULATION; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 77549088452     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.11.010     Document Type: Article

References (28)

1. Galie N., Torbicki A., Barst R., Dartevelle P., Haworth S., Higenbottam T., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 25 24 (2004) 2243-2278
2. Farber H.W., and Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 351 16 (2004) 1655-1665
3. Ghofrani H.A., Wilkins M.W., and Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 118 11 (2008) 1195-1201
4. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 2 (1992) 76-81
5. Sitbon O., Humbert M., Jais X., Ioos V., Hamid A.M., Provencher S., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 23 (2005) 3105-3111
6. Weir E.K., Rubin L.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the national institutes of health registry on primary pulmonary hypertension. Am Rev Respir Dis 140 6 (1989) 1623-1630
7. Badesch D.B., Abman S.H., Simonneau G., Rubin L.J., and McLaughlin V.V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131 6 (2007) 1917-1928
8. McLaughlin V.V., Archer S.L., Badesch D.B., Barst R.J., Farber H.W., Lindner J.R., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. A report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association. Circulation 119 (2009) 2250-2294
9. Hoeper M.M., Lee S.H., Voswinckel R., Palazzini M., Jais X., Marinelli A., et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 48 12 (2006) 2546-2552
10. Morgan J.M., McCormack D.G., Griffiths M.J., Morgan C.J., Barnes P.J., and Evans T.W. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 84 3 (1991) 1145-1149
11. Nootens M., Schrader B., Kaufmann E., Vestal R., Long W., and Rich S. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 107 1 (1995) 54-57
12. Schrader B.J., Inbar S., Kaufmann L., Vestal R.E., and Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 19 5 (1992) 1060-1064
13. Berner M., Beghetti M., Spahr-Schopfer I., Oberhansli I., and Friedli B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol 77 7 (1996) 532-535
14. Nihil M.R. Clinical management of patients with pulmonary hypertension. In: Emmanouilides G.C., Riemenschneider T.A., Allen H.D., and Gutgesell H.P. (Eds). Moss and Adams heart disease in infants, children, and adolescents (1995), Williams & Wilkins, Baltimore 1695-1711
15. Klings E.S., Hill N.S., Ieong M.H., Simms R.W., Korn J.H., and Farber H.W. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 42 12 (1999) 2638-2645
16. Simonneau G., Fartoukh M., Sitbon O., Humbert M., Jagot J.L., and Herve P. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 114 Suppl. 3 (1998) 195S-199S
17. Pepke-Zaba J., Higenbottam T.W., Dinh-Xuan A.T., Stone D., and Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338 8776 (1991) 1173-1174
18. Sitbon O., Humbert M., Jagot J.L., Taravella O., Fartoukh M., Parent F., et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12 2 (1998) 265-270
19. Hoeper M.M., Olschewski H., Ghofrani H.A., Wilkens H., Winkler J., Borst M.M., et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 35 1 (2000) 176-182
20. Blomstrom-Lundqvist C., Scheinman M.M., Aliot E.M., Alpert J.S., Calkins H., Camm A.J., et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol 42 8 (2003) 1493-1531
21. Tabrizchi R., and Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol Ther 91 2 (2001) 133-147
22. Paidas C.N., Dudgeon D.L., Haller Jr. J.A., and Clemens M.G. Adenosine triphosphate: a potential therapy for hypoxic pulmonary hypertension. J Pediatr Surg 23 12 (1988) 1154-1160
23. Paidas C.N., Dudgeon D.L., Haller Jr. J.A., and Clemens M.G. Adenosine triphosphate (ATP) treatment of hypoxic pulmonary hypertension (HPH): comparison of dose dependence in pulmonary and renal circulations. J Surg Res 46 4 (1989) 374-379
24. Konduri G.G., Garcia D.C., Kazzi N.J., and Shankaran S. Adenosine infusion improves oxygenation in term infants with respiratory failure. Pediatrics 97 3 (1996) 295-300
25. Fullerton D.A., Jaggers J., Jones S.D., Brown J.M., and McIntyre Jr. R.C. Adenosine for refractory pulmonary hypertension. Ann Thorac Surg 62 3 (1996) 874-877
26. Fullerton D.A., Kirson L.E., Jones S.D., and McIntyre Jr. R.C. Adenosine is a selective pulmonary vasodilator in cardiac surgical patients. Chest 109 1 (1996) 41-46
27. Ng C., Franklin O., Vaidya M., Pierce C., and Petros A. Adenosine infusion for the management of persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 5 1 (2004) 10-13
28. Tricoci P., Allen J.M., Kramer J.M., Califf R.M., and Smith Jr. S.C. Scientific evidence underlying the ACC/AHA clinical practice guidelines. J Am Med Assoc 301 8 (2009) 831-841